5.2 Cytochrome P450 Systems & High-Risk Drug Interactions

[!NOTE] Curriculum Focus: The MRCP(UK) Part 1 consistently tests mechanisms of adverse drug-drug interactions. Candidates are expected to identify the specific CYP isoenzyme responsible for metabolising key cardiovascular, neurological, and immunosuppressive agents, distinguish enzyme inducers from inhibitors, understand the timeline of enzyme modulation, and anticipate critical non-CYP pharmacokinetic interactions.

Hepatic drug metabolism transforms lipophilic xenobiotics into polar, water-soluble metabolites suitable for renal or biliary elimination. This biotransformation occurs in two consecutive phases:

• Phase I Reactions (Functionalisation): Introduce or unmask polar functional groups (-OH, -NH2, -SH, -COOH) via oxidation, reduction, or hydrolysis. Predominantly catalysed by the Cytochrome P450 (CYP450) superfamily of haemoprotein monooxygenases embedded in the smooth endoplasmic reticulum.
• Phase II Reactions (Conjugation): Covalently couple the drug or Phase I metabolite with an endogenous hydrophilic molecule via glucuronidation (UGT), sulfation (SULT), glutathione conjugation (GST), or acetylation (NAT). Phase II reactions are generally preserved longer than Phase I oxidations in patients with advancing liver cirrhosis.

---

Overview of Critical CYP Isoforms and Pharmacogenomics

Although dozens of CYP isoforms exist, five distinct isoenzymes handle over 90% of clinically significant drug biotransformations:

+-----------------------------------------------------------------------------------------+
|                        Major Cytochrome P450 Isoforms                                   |
+-----------------------------------------------------------------------------------------+
| CYP3A4  • Abundance: ~30% of hepatic CYP; metabolises > 50% of prescription drugs       |
|         • Substrates: Statins, Calcineurin inhibitors, DOACs, Calcium blockers          |
|                                                                                         |
| CYP2D6  • Abundance: ~2% of hepatic CYP; metabolises ~25% of prescription drugs         |
|         • Highly polymorphic: Poor vs Ultra-Rapid metabolisers (codeine, tamoxifen)     |
|                                                                                         |
| CYP2C9  • Key Substrates: S-warfarin (active), Phenytoin, Sulfonylureas, NSAIDs         |
|                                                                                         |
| CYP2C19 • Key Substrates: Clopidogrel bioactivation, Omeprazole, Diazepam              |
|                                                                                         |
| CYP1A2  • Key Substrates: Theophylline, Clozapine; strongly induced by cigarette smoke |
+-----------------------------------------------------------------------------------------+

1. CYP3A4: The Dominant Metabolic Engine

CYP3A4 is the most abundant isoform in both the liver and the intestinal epithelium. It exhibits broad substrate specificity, rendering it exceptionally vulnerable to competitive inhibition and transcriptional upregulation.

• High-Risk Substrates: Statins (simvastatin, atorvastatin; notably not pravastatin or rosuvastatin), calcineurin inhibitors (tacrolimus, ciclosporin), direct oral anticoagulants (rivaroxaban, apixaban), dihydropyridine calcium channel blockers, phosphodiesterase-5 inhibitors (sildenafil), and oral midazolam.

2. CYP2D6: Pharmacogenomic Polymorphisms and Prodrug Activation

CYP2D6 is genetically non-inducible but exhibits profound genetic polymorphism governed by autosomal recessive alleles and gene duplication events:

• Poor Metabolisers (5–10% of Caucasians): Possess inactive CYP2D6 alleles (*4, *5). They cannot activate prodrugs that depend on CYP2D6 cleavage:
  • Codeine & Tramadol: Codeine is an inactive prodrug requiring CYP2D6 O-demethylation into morphine to produce analgesia. Poor metabolisers experience zero pain relief.
  • Tamoxifen: Requires CYP2D6 conversion to its 100-fold more active anti-oestrogenic metabolite, endoxifen. Poor metabolisers (or women co-prescribed potent CYP2D6 inhibitors like fluoxetine or paroxetine) experience significantly higher rates of breast cancer recurrence.
• Ultra-Rapid Metabolisers (up to 20–30% of North/East African populations): Possess multiple functional gene copies (up to 13 copies). Therapeutic doses of codeine produce rapid, massive generation of free morphine, resulting in life-threatening respiratory depression, coma, and neonatal fatalities via breast milk.

3. CYP2C9: S-Warfarin and Narrow Therapeutic Index Drugs

Warfarin is administered as a racemic mixture of R- and S-enantiomers. The S-enantiomer is 3- to 5-times more potent than the R-enantiomer and is cleared exclusively by CYP2C9. Polymorphic variants (CYP2C92 and CYP2C93) exhibit impaired clearance, predisposing patients to catastrophic haemorrhage on standard induction doses.

4. CYP2C19: Clopidogrel Bioactivation

Clopidogrel is an inactive thienopyridine prodrug that requires a two-step hepatic oxidation, heavily reliant on CYP2C19, to generate its active thiol platelet-inhibitor metabolite. Concomitant use of omeprazole (a potent CYP2C19 inhibitor) blunts clopidogrel antiplatelet efficacy, increasing stent thrombosis rates. In contrast, pantoprazole exhibits minimal CYP2C19 inhibition and is the proton-pump inhibitor of choice in patients receiving dual antiplatelet therapy.

5. CYP1A2: Cigarette Smoke Interactions

CYP1A2 metabolises theophylline, caffeine, clozapine, and olanzapine. The polycyclic aromatic hydrocarbons present in cigarette smoke (not nicotine itself) potently induce CYP1A2. When a psychiatric patient stabilised on clozapine abruptly ceases smoking upon hospital admission, CYP1A2 de-induces, precipitating severe clozapine toxicity (sedation, seizures, agranulocytosis).

---

High-Yield Matrix: Potent CYP Inducers vs Inhibitors

Understanding the biochemical timeline is clinically crucial: inhibition occurs immediately (within hours) as the inhibitor competes for the enzyme catalytic site; induction requires 7–14 days to manifest because it requires nuclear receptor transcription (PXR, CAR) and de novo enzyme protein synthesis, and persists for 1–3 weeks following drug discontinuation.

[!WARNING] Grapefruit Juice & Intestinal CYP3A4: Grapefruit juice contains furanocoumarins (e.g., bergamottin) that selectively and irreversibly destroy enterocyte (intestinal wall) CYP3A4 via suicide inhibition, without affecting hepatic CYP3A4. This selectively annihilates the oral first-pass extraction of substrates, increasing simvastatin bioavailability up to 15-fold and causing fulminant rhabdomyolysis.

---

Critical Non-CYP Pharmacokinetic & Pharmacodynamic Interactions

Beyond the CYP450 superfamily, the MRCP Part 1 frequently tests three life-threatening non-CYP interaction mechanisms:

1. P-Glycoprotein (MDR1 / ABCB1) Transporter Interactions

P-glycoprotein is an ATP-dependent efflux pump located on the apical membranes of enterocytes (pumps drug back into intestinal lumen), renal proximal tubular cells (pumps drug into urine), biliary canaliculi (pumps into bile), and brain capillary endothelial cells (blood-brain barrier defense).

• P-gp Substrates: Digoxin, dabigatran etexilate, rivaroxaban, ciclosporin, loperamide.
• P-gp Inhibitors: Amiodarone, Verapamil, Clarithromycin, Quinidine, Diltiazem.
• Clinical Disaster: Adding amiodarone or verapamil to a stable digoxin regimen inhibits renal and intestinal P-gp excretion, doubling serum digoxin concentrations and precipitating complete heart block. When starting amiodarone, the digoxin dose must immediately be halved by 50%.

2. Methotrexate and Organic Anion Transporter (OAT) Competition

Methotrexate is cleared predominantly by active renal proximal tubular secretion mediated by Organic Anion Transporters 1 and 3 (OAT1/OAT3).

• Interacting Drugs: NSAIDs (ibuprofen, naproxen), Penicillins (piperacillin-tazobactam, amoxicillin), and Proton Pump Inhibitors compete directly for OAT binding sites, dramatically reducing methotrexate clearance.
• Cotrimoxazole (Trimethoprim-Sulfamethoxazole): Possesses a lethal dual interaction with methotrexate: sulfamethoxazole displaces methotrexate from albumin, and trimethoprim inhibits both renal tubular excretion and acts as a synergistic inhibitor of dihydrofolate reductase (DHFR). This combination induces fulminant bone marrow aplasia (pancytopenia), mucositis, and sepsis.

+------------------------------------------------------------------------------------------+
|                       Methotrexate & Cotrimoxazole Dual Toxicity                         |
+------------------------------------------------------------------------------------------+
|  [Sulfamethoxazole] -------> Displaces Methotrexate from Albumin                         |
|                                          |                                               |
|  [Trimethoprim] -----------> Blocks Renal OAT1/OAT3 Secretion                            |
|                                          v                                               |
|                             Massive Surge in Free Methotrexate                           |
|                                          +                                               |
|  [Trimethoprim] -----------> Synergistic Dihydrofolate Reductase (DHFR) Blockade         |
|                                          v                                               |
|                             Pancytopenia & Bone Marrow Aplasia                           |
+------------------------------------------------------------------------------------------+

3. Synergistic Hyperkalaemia Pathways

Potassium homeostasis is exquisitely sensitive to multi-drug regimens affecting the distal nephron:

• The Triad: Combining ACE inhibitors / ARBs (diminish aldosterone secretion) with Potassium-sparing diuretics (spironolactone, eplerenone, amiloride) and Trimethoprim.
• Trimethoprim Mechanism: Trimethoprim has a chemical structure closely resembling the potassium-sparing diuretic amiloride. It competitively blocks the epithelial sodium channel (ENaC) in the apical membrane of the renal collecting tubule, eliminating the lumen-negative transepithelial potential required for potassium excretion. Co-prescribing trimethoprim with spironolactone or ramipril routinely precipitates emergency refractory hyperkalaemia (K+ > 7.0 mmol/L) and fatal ventricular arrhythmias.